Evidence map›Paper›PMID 34935105›Full record

ReviewClinical drug investigation2022

Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations.

Amnon A Berger, Christopher Robinson, Ariel Winnick, Jonathan Izygon, Binil M Jacob, Mackenzie J Noonan, Alan D Kaye, Jessica S Kaye, Adam M Kaye, Elyse M Cornett and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical drug investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Amnon A BergerDepartment of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Christopher RobinsonDepartment of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ariel WinnickSoroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Jonathan IzygonSoroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Binil M JacobSoroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Mackenzie J NoonanDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Alan D KayeDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Jessica S KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA.
Elyse M CornettDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. ecorne@lsuhsc.edu.
Rutvij J ShahDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Omar ViswanathDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA.
Ivan UritsDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Ben-Gurion University of the Negev · ILLouisiana State University Health Sciences Center Shreveport · USUniversity of the Pacific · USBeth Israel Deaconess Medical Center · USCreighton University · USHarvard University · USSouthCoast Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder. It is also the fastest-growing neurodegenerative disorder and has more than doubled between 1990 and 2016. Parkinson's disease causes significant morbidity and disability from motor dysfunction, sleep disturbances, and cognitive and psychiatric symptoms. This paper reviews recent evidence in the treatment of PD "off" episodes with the novel drug opicapone, including its efficacy, safety, and clinical indications. Opicapone is a novel, peripherally acting catechol-O-methyl transferase (COMT) inhibitor used as adjunctive therapy to carbidopa/levodopa for treatment and prevention of "off" episodes. It has been approved for use as an adjunct to levodopa since 2016 in Europe and has recently (April 2020) gained FDA approval for use in the USA. By inhibiting COMT, opicapone slows levodopa metabolism and increases its availability. Several clinical studies demonstrated significant improvement in treatment efficacy and reduction in the duration of "off" episodes The main side effect demonstrated was dyskinesia, mostly with the 100 mg dose, which is higher than the approved, effective dose of 50 mg.

Indexed as

Parkinson DiseaseAntiparkinson AgentsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsHumansOxadiazolesAntiparkinson AgentsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsopicaponeOxadiazoles

Identifiers

PMID34935105
OpenAlexW4200514396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.